← The SEC Ephemeris: the whole map
Impax Laboratories, LLC Crexont Extended Release
In the graph: all 1 documents (3 pages).
- Application
- NDA 217186
- Ticker
- Impax Laboratories, LLC
- Product
- Crexont Extended Release
- Disease area
- Not yet classified
- Response path
- Not yet classified
- Complete Response Letters
- June 30, 2023
From FDA letters and SEC filings. Not investment or medical advice.